H

Halozyme Therapeutics
D

HALO

49.010
USD
3.29
(7.20%)
Market Closed
Volume
132,490
EPS
3
Div Yield
-
P/E
16
Market Cap
6,235,395,270
Related Instruments
    B
    BMRN
    -2.200
    (-3.35%)
    63.440 USD
    C
    CRIS
    -0.04000
    (-1.00%)
    3.96000 USD
    NVS
    NVS
    -0.350
    (-0.34%)
    104.29 USD
    O
    ONCS
    -0.01000
    (-0.44%)
    2.16000 USD
    S
    SGMO
    -0.10000
    (-4.67%)
    2.04000 USD
    X
    XENE
    -1.920
    (-4.60%)
    39.850 USD
    X
    XLRN
    0
    (0%)
    0.000000 USD
    More
News

Title: Halozyme Therapeutics

Sector: Healthcare
Industry: Biotechnology
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.